Osteoarthritis
Conditions
Keywords
Osteoarthritis, Pain
Brief summary
ThermoProfen is a transdermal ketoprofen patch that is integrated with a long-lasting CHADD (Controlled Heat-Assisted Drug Delivery) unit for the treatment of chronic pain associated with osteoarthritis. This study will evaluate ThermoProfen for the treatment of mild to moderate pain associated with osteoarthritis of the knee in adults.
Detailed description
The primary objective of the study is to compare the efficacy of ThermoProfen™ against two other experimental treatments. The treatment may be ThermoProfen (Matrix Transdermal Ketoprofen Patch) or a patch that may or may not include ketoprofen and that may or may not provide heat.
Interventions
DRUGKetoprofen matrix/placebo CHADD Patch
Transdermal knee applied to the knee for 12 hours daily.
Transdermal patch applied to the knee for 12 hours daily.
DRUGPlacebo Matrix/CHADD Patch
Transdermal patch applied to the knee for 12 hours daily.
Sponsors
ZARS Pharma Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Patient is 18 through 75 years of age * Patient has radiographic evidence of osteoarthritis of the target knee obtained within the past year.
Exclusion criteria
* Patient has a known allergy to nonsteroidal anti-inflammatory drugs (NSAIDs, including aspirin). * Patient has asthma that has been induced or made worse by the use of aspirin or NSAIDs. * Patient has a relevant history of serious gastrointestinal disease. * Patient, if female, is pregnant or breastfeeding or is of childbearing potential and not practicing adequate birth control. * Patient is taking warfarin, heparin, or low molecular weight heparin. * Patient has received oral, intramuscular, intravenous, intra-articular, or soft-tissue administration of steroids within 1 month of study enrollment (or within 2 months, if in the target joint). * Patient has received intra-articular visco-supplementation (in target joint) within 6 months of study enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome measure is the change from baseline in the Visual Analog Scale score for the average pain during the previous 24 hours. | 12 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Change from baseline in Visual Analog Scale score for worst pain during the previous 24 hours, amount of rescue medication used to treat the target joint per day, and the patient global impression of change in the Likert Scale | 12 weeks |
Countries
United States
Outcome results
None listed